Kymriah (tisagenlecleucel-T) / University of Pennsylvania, Novartis  >>  Phase 1
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kymriah (tisagenlecleucel-T) / Novartis
NCT01551043: Allo CART-19 Protocol

Terminated
1
2
US
CART-19
University of Pennsylvania
Acute Lymphocytic Leukemia
05/15
06/16
NCT01029366: CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
1
26
US
CART-19
University of Pennsylvania
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
07/15
05/16
NCT02135406: CART-19 for Multiple Myeloma

Completed
1
13
US
CART-19 T cells
University of Pennsylvania
Multiple Myeloma
09/15
01/18
NCT02277522: CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Terminated
1
4
US
RNA anti-CD19 CAR T cells
University of Pennsylvania
Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
11/16
06/17
NCT02640209: Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

Terminated
1
20
US
CART 19
University of Pennsylvania
LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
10/18
07/19
NCT02624258: Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Terminated
1
2
US
CD19 RNA redirected autologous T-cells (RNA CART19 cells)
University of Pennsylvania, Children's Hospital of Philadelphia
Hodgkin Lymphoma
06/19
12/19
NCT02906371: Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

Completed
1
80
US
Tocilizumab, high tumor burden, low tumor burden, CART 19
University of Pennsylvania, Children's Hospital of Philadelphia
Lymphoblastic Leukemia, Acute, Childhood
03/20
06/21
PORTIA, NCT03630159: Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

Completed
1
12
Europe, Canada, US
Tisagenlecleucel, CTL019, Pembrolizumab
Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma
07/21
07/21
NCT04134117: Tisagenlecleucel in Primary CNS Lymphoma

Completed
1
6
US
Tisagenlecleucel, KYMRIAH
Matthew J. Frigault, M.D., Novartis
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
04/22
04/22
NCT03876028: Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Terminated
1
10
US
Tisagenlecleucel, Ibrutinib
Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma
11/21
11/21
NCT02529813: CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Completed
1
26
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Ziopharm Oncology
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
11/21
11/21
NCT06408194: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Recruiting
1
20
US
CD22CART infusion, Tisagenlecleucel, KYMRIAH
Stanford University
Leukemia, Acute Lymphoblastic Leukemia
06/25
06/25
NCT04890236: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recruiting
1
20
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
Emory University, National Cancer Institute (NCI), Secura Bio, Inc., Novartis
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
08/24
08/25
NCT05075603: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Recruiting
1
57
US
Efineptakin alfa, NT-I7, rhIL-7-hyFc, Tisagenlecleucel, Kymriah, Axicabtagene ciloleucel, Yescarta, Lisocabtagene Maraleucel, Breyanzi
NeoImmuneTech
Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
11/24
02/26
NCT05037669: Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

Withdrawn
1
0
NA
PACE CART19
University of Pennsylvania
Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
01/25
01/38
LOKI, NCT06003179: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

Recruiting
1
40
Canada
Cyclophosphamide, Cytoxan, neosar, TLI, Fludarabine
University Health Network, Toronto
Lymphoma, Large B-Cell, Diffuse
11/26
11/28
NCT04419909: Retreatment With CTL019/CTL119

Not yet recruiting
1
12
US
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
University of Pennsylvania
Lymphoma, B-Cell
07/27
07/27

Download Options